Skip to main content
    G

    Ginkgo Bioworks Holdings (DNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $9.61
    -0.62 (-6.06%)

    Market Cap: $622.97M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Ginkgo Bioworks Holdings (DNA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Ginkgo Bioworks Holdings reported revenue of $170.16M for the fiscal year ended Dec 31, 2025, down 25.1% from the year before. That year, net income was -$312.76M with a net margin of -183.8%, operating cash flow was -$171.06M and free cash flow was -$178.72M. The quarter ended Sep 30, 2026 had revenue of $27.71M and net income of -$40.98M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue grew from $54.18M, a compound annual rate of 21.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$170.16M-25.1%72.4%-185.3%-183.8%
    Dec 2024$227.04M-9.7%80.4%-246.5%-240.9%
    Dec 2023$251.46M-47.4%78.5%-343.8%-355.1%
    Dec 2022$477.71M+52.2%57.3%-462.4%-440.9%
    Dec 2021$313.84M+309.4%58.7%-582.6%-585.2%
    Dec 2020$76.66M+41.5%79.6%-178.8%-165.3%
    Dec 2019$54.18MN/A100.0%-132.1%-221.2%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$170.16M$227.04M$251.46M$477.71M$313.84M$76.66M$54.18M
    Cost of revenue$46.97M$44.55M$54.01M$204.22M$129.69M$15.61M$0
    Gross profit$123.18M$182.50M$197.45M$273.49M$184.15M$61.05M$54.18M
    Research and development$243.77M$424.06M$580.62M$1.05B$1.15B$159.77M$96.30M
    Operating income-$315.28M-$559.76M-$864.41M-$2.21B-$1.83B-$137.03M-$71.60M
    Net income-$312.76M-$547.03M-$892.87M-$2.11B-$1.84B-$126.72M-$119.86M
    EBITDA-$260.81M-$487.17M-$779.59M-$2.03B-$1.72B-$107.04M-$57.68M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$27.71M$20.16M$19.47M$33.40M$29.38M$39.13M$38.23M$43.85M$89.05M$56.21M$37.94M$34.76M
    Gross profit$25.91M$18.44M$16.38M$41.90M$24.75M$33.75M$34.14M$55.23M$77.04M$30.68M$19.54M$28.14M
    Operating income-$43.63M-$58.55M-$71.37M-$65.94M-$82.31M-$58.16M-$80.97M-$100.16M-$55.20M-$226.39M-$178.00M-$178.12M
    Net income-$40.98M-$46.71M-$82.59M-$80.75M-$80.75M-$60.30M-$90.96M-$107.53M-$56.40M-$217.18M-$165.91M-$211.69M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $22.81M by $144.40M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$1.12B$1.38B$1.67B$2.54B$2.07B$675.15M$697.32M
    Current assets$471.84M$602.74M$1.00B$1.45B$1.72B$426.54M$511.93M
    Cash and equivalents$167.20M$561.57M$944.07M$1.32B$1.55B$380.80M$495.29M
    Total liabilities$611.11M$661.39M$568.19M$803.04M$503.61M$205.10M$195.47M
    Short-term debt$22.81M$28.96M$17.47M$29.33M$747.00K$485.00K$598.00K
    Shareholder equity$508.59M$716.06M$1.10B$1.74B$1.51B$461.38M$493.06M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$944.45M$990.05M$1.03B$1.12B$1.19B$1.23B$1.29B$1.38B$1.48B$1.63B$1.58B$1.67B
    Total liabilities$551.82M$569.76M$589.92M$611.11M$629.38M$618.06M$646.04M$661.39M$682.94M$792.18M$594.49M$568.19M
    Cash and equivalents$84.50M$84.53M$143.86M$167.20M$111.06M$203.57M$312.42M$561.57M$616.21M$730.37M$840.44M$944.07M
    Shareholder equity$392.64M$420.28M$443.15M$508.59M$559.78M$612.95M$647.43M$716.06M$797.94M$833.07M$987.27M$1.10B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$171.06M-$319.58M-$295.50M-$252.20M-$253.82M-$135.83M-$44.66M
    Capital expenditures$7.67M$62.54M$40.80M$52.27M$56.52M$57.82M$22.22M
    Free cash flow-$178.72M-$382.13M-$336.30M-$304.47M-$310.34M-$193.65M-$66.88M
    Dividends paidN/AN/AN/A$981.00K$1.51BN/AN/A
    Share repurchasesN/A$0$0$1.47M$25.00M$0$408.00K
    Investing cash flow-$240.29M-$62.24M-$80.69M-$67.39M-$73.26M-$67.12M-$74.60M
    Financing cash flow$17.77M-$1.74M-$3.22M$95.34M$1.53B$90.32M$410.38M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$28.35M-$44.27M-$46.69M-$47.68M-$31.61M-$40.25M-$51.52M-$42.44M-$103.50M-$84.39M-$89.26M-$57.83M
    Capital expenditures$2.00M$2.62M$1.93M$5.00K$7.66M$38.00K$7.62M$13.71M$15.09M$27.03M$6.71M$3.45M
    Free cash flow-$30.35M-$46.89M-$48.62M-$47.68M-$39.27M-$40.29M-$59.14M-$56.15M-$118.59M-$111.42M-$95.97M-$61.28M
    Last 12 quarters

    Frequently Asked Questions About DNA

    What is Ginkgo Bioworks Holdings' annual revenue?

    Ginkgo Bioworks Holdings reported revenue of $170.16M for the fiscal year ended Dec 31, 2025.

    How fast is Ginkgo Bioworks Holdings' revenue growing?

    Revenue was down 25.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -29.1%.

    Is Ginkgo Bioworks Holdings profitable?

    No. Ginkgo Bioworks Holdings reported net income of -$312.76M for the fiscal year ended Dec 31, 2025, with a net margin of -183.8%.

    How much free cash flow does DNA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$171.06M minus capital expenditures of $7.67M produced free cash flow of -$178.72M.

    How much debt does Ginkgo Bioworks Holdings have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $22.81M and cash and equivalents of $167.20M.